Sanuwave Announces Record Revenues and Financial Results for Q4 and Full Year 2025 Q4 2025 revenues were $13.4 million , up 29.7% from Q4 2024. This was an all-time quarterly record for the Company. Full year 2025 revenues were $44.1 million up 35.0% from full year 2024 revenues. This was an all-time annual record for the Company. Q4 2025 gross margin was 74.7% , versus 77.9% in

#SNWV Sanuwave Announces Record Revenues and Financial Results for Q4 and Full Year 2025

www.stocktitan.net/news/SNWV/sanuwave-annou...

Sanuwave Health Announces Preliminary Q4 2025 Revenue of $13.3–$13.4 Million, Up 29–30% Year-over-Year; Achieves Record Quarterly and Full-Year Revenue Sanuwave Health (NASDAQ: SNWV) reported preliminary Q4 2025 revenue of $13.3–$13.4 million, a 29–30% increase versus Q4 2024 and the company’s highest quarterly revenue ever. Full-year 2025 revenue rose to $44.3–$44.4 million, up 36% year-over-year and a record for the company. Management said Q4 results are within prior guidance and are based on preliminary quarter-end analysis that may be adjusted during financial close. The company noted market disruption from reduced reimbursement for skin-substitutes and allografts, and said it is adding partners and sales channels while adapting its business model. Final audited results and further detail will be released with the March earnings report.

#SNWV Sanuwave Health Announces Preliminary Q4 2025 Revenue of $13.3–$13.4 Million, Up 29–30% Year-over-Year; Achieves Record Quarterly and Full-Year Revenue

www.stocktitan.net/news/SNWV/sanuwave-healt...

Sanuwave Announces the Addition of UltraMIST to Healogics Group Purchasing Organization (GPO), iSupply Sanuwave (NASDAQ: SNWV) announced that its UltraMIST wound-care system has been added to Healogics iSupply, the Healogics Group Purchasing Organization, making UltraMIST an option for iSupply members including Wound Care Centers, home health agencies, and skilled nursing facilities.Sanuwave said it plans to roll out the UltraMIST system to initial iSupply locations by the end of 2025. The companies described the arrangement as a collaboration intended to provide a cost-saving, FDA-approved wound healing option to Healogics members.

#SNWV Sanuwave Announces the Addition of UltraMIST to Healogics Group Purchasing Organization (GPO), iSupply

www.stocktitan.net/news/SNWV/sanuwave-annou...

Sanuwave Announces Q3 FY2025 Financial Results Sanuwave (NASDAQ: SNWV) reported Q3 FY2025 revenue of $11.5M, up 22% year‑over‑year and a sequential increase of 13%, marking the company's highest quarterly revenue on record.Q3 gross margin was 77.9%. GAAP operating income was $1.5M after $1.4M of stock‑based compensation. Net income was $10.3M, driven by a $6.1M non‑cash gain on derivative liabilities and a $5.0M patent sale. Adjusted EBITDA was $3.5M.The company forecasted Q4 2025 revenue $13–$14M and full‑year revenue of $44–$45M (a 35–39% increase vs 2024).

#SNWV Sanuwave Announces Q3 FY2025 Financial Results

www.stocktitan.net/news/SNWV/sanuwave-annou...

CMS Publishes Final Rule for Calendar Year 2026 Physician Fee Schedule for UltraMIST Procedure (CPT code 97610) CMS adopts Final Rule for 2026 Physician Fee Schedule in line with proposed rule for CPT code 97610 2026 rates for physician offices, home visits, long-term care, and hospitals are in line with the proposed rule and remain materially unchanged from 2025 EDEN PRAIRIE, Minn., Nov. 03, 2025 (GLOBE

#SNWV CMS Publishes Final Rule for Calendar Year 2026 Physician Fee Schedule for UltraMIST Procedure (CPT code 97610)

www.stocktitan.net/news/SNWV/cms-publishes-...

PRISM Morning Movers:
Top Gainers:
#Galecto, Inc. ( #GLTO) - up 726%
#C3is Inc. ( #CISS) - up 55%
#SpruceBiosciences, Inc. ( #SPRB) - up 41%
#LexeoTherapeutics, Inc. ( #LXEO) - up 32%
Top Decliners:
#SocietyPass Incorporated ( #SOPA) - down 25%
#SANUWAVE Health, Inc. ( #SNWV) - down 18%

Sanuwave Health Announces Preliminary Revenue Results for the Third Quarter 2025 (Ended September 30, 2025) Sanuwave (NASDAQ: SNWV) reported preliminary Q3 2025 revenues of $11.4M–$11.6M, the highest quarterly revenue in company history, up 22%–24% vs Q3 2024 and 12%–14% sequentially. First nine months 2025 revenue rose 39%–40% vs YTD 2024. Q3 results missed prior guidance of $12.0M–$12.7M and management lowered 2025 annual revenue guidance from $48M–$50M to $44M–$46M. Company cited near-term reimbursement uncertainty for some wound-care modalities that delayed purchases, but said UltraMIST reimbursement (97610) is not affected and may increase slightly in 2026. Full Q3 2025 results are planned for release on or around November 7, 2025.

#SNWV Sanuwave Health Announces Preliminary Revenue Results for the Third Quarter 2025 (Ended September 30, 2025)

www.stocktitan.net/news/SNWV/sanuwave-healt...

Sanuwave Health is a buy, this analyst says Roth Capital Markets analyst Kyle Bauser reiterated a “Buy” rating and US$55.00 target price on Sanuwave Health

Sanuwave Health is a buy, this analyst says Roth Capital Markets analyst Kyle Bauser reiterated a “Buy” rating and US$55.00 target price for Sanuwave Health (Sanuwave Health Stock Quote, Chart,...

#All #posts #American #Tech #Analysts #SNWV

Origin | Interest | Match

Sanuwave Announces Strategic Debt Refinancing with New Credit Facility Sanuwave Health (NASDAQ: SNWV), a leading provider of FDA-approved wound care products, has successfully refinanced its debt through a new credit facility with J.P. Morgan. The facility includes a $23 million four-year term loan and a $5 million two-year revolving credit facility backed by accounts receivable.The new arrangement replaces the company's previous $27.5 million debt facility with NH Expansion. At closing, Sanuwave drew approximately $24 million total, including $1 million from the revolving facility. Both facilities carry an interest rate of SOFR +350bp with no prepayment penalties. The remaining balance and transaction costs of approximately $4.8 million were paid using operational cash flow and proceeds from a recent patent sale.

#SNWV Sanuwave Announces Strategic Debt Refinancing with New Credit Facility

www.stocktitan.net/news/SNWV/sanuwave-annou...

Sanuwave Announces Q2 FY2025 Financial Results Sanuwave Health (NASDAQ: SNWV) reported strong Q2 2025 financial results, achieving record quarterly revenues of $10.2 million, up 42% year-over-year. The company demonstrated improved profitability with a gross margin of 78.3%, up from 73.2% in Q2 2024.Key highlights include the sale of 116 UltraMist® systems in Q2 2025, up from 72 in Q2 2024, and UltraMist® consumables revenue increased by 37% to $6.4 million. Operating income was $1.9 million, with net income of $1.1 million. The company achieved Adjusted EBITDA of $3.4 million, more than double the $1.5 million from Q2 2024.Looking ahead, Sanuwave provided guidance for Q3 2025 revenue of $12-$12.7 million and maintained its full-year 2025 revenue guidance of $48-$50 million, representing a 47-53% increase from 2024.

#SNWV Sanuwave Announces Q2 FY2025 Financial Results

www.stocktitan.net/news/SNWV/sanuwave-annou...

Sanuwave Health Announces Preliminary Revenue Results for the Second Quarter 2025 (Ended June 30, 2025) Sanuwave Health (NASDAQ:SNWV), a leading provider of FDA-approved wound care products, reported preliminary Q2 2025 revenues of $10.1-$10.2 million, marking its highest Q2 revenue in company history. This represents a 41-42% increase compared to Q2 2024.The company has undergone significant commercial expansion, including the appointment of a new head of sales and commercial operations. By July, Sanuwave will have 13 sales representatives covering all national territories, plus a dedicated national accounts manager for larger opportunities. The first half of 2025 showed strong performance with a 50-51% revenue increase compared to the first half of 2024.Full Q2 2025 results will be released around August 8th, 2025.

#SNWV Sanuwave Health Announces Preliminary Revenue Results for the Second Quarter 2025 (Ended June 30, 2025)

www.stocktitan.net/news/SNWV/sanuwave-healt...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with improving money flow, Tue Jul 8th - #HIFS #GAME #FTFT #CVAC #BWMN #API #CARS #BUR #ARMN #ICCM #LGVN #NBBK #OBLG #PROK #RWAY #SNWV #TLRY #WKHS - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Sanuwave Health Joins Russell 2000: What This Means for $10.6T Institutional Investment Exposure Next-gen wound care leader secures spot in prestigious Russell indexes, opening doors to $10.6T institutional investment benchmark. See growth implications.

#SNWV Sanuwave Health Selected for Inclusion in Russell 2000® Index

www.stocktitan.net/news/SNWV/sanuwave-healt...

Sanuwave Announces Q1 FY2025 Financial Results Sanuwave Health (NASDAQ: SNWV) reported strong Q1 2025 financial results with record-breaking quarterly performance. Revenue reached $9.3 million, up 61% from Q1 2024, exceeding guidance of 45-55% growth. The company's gross margin improved to 79.0% from 72.6% year-over-year. UltraMist® system sales increased to 98 units (up 128% YoY), while consumables revenue grew 43% to $5.8 million. The company achieved operating income of $1.0 million, a $2.0 million improvement from Q1 2024. Adjusted EBITDA was $2.3 million compared to -$59,000 in Q1 2024. Despite operational improvements, net loss was $5.7 million due to derivative liabilities. Looking ahead, Sanuwave forecasts Q2 2025 revenue of $10.0-10.7 million (40-50% YoY growth) and maintains full-year 2025 guidance of $48-50 million.

#SNWV Sanuwave Announces Q1 FY2025 Financial Results

www.stocktitan.net/news/SNWV/sanuwave-annou...

SANUWAVE Crushes Expectations: Q1 Revenue Soars 61% to All-Time High Record-breaking quarter driven by 65% UltraMIST growth despite leadership transition. See full analysis of SANUWAVE's strongest Q1 performance ever.

#SNWV SANUWAVE Health Announces Preliminary Revenue Results for the First Quarter 2025 (Ended March 31, 2025)

www.stocktitan.net/news/SNWV/sanuwave-healt...

SANUWAVE Announces Record Quarterly Revenues: Q4 FY2024 Financial Results SANUWAVE Health (NASDAQ: SNWV) reported record-breaking financial results for Q4 and full year 2024. Q4 revenues reached $10.3 million, up 47% year-over-year, with a gross margin of 77.9%. Full-year 2024 revenues hit $32.6 million, increasing 60% from 2023.Key Q4 highlights include:135 UltraMist® systems sold (up from 79 in Q4 2023)UltraMist® consumables revenue grew 59% to $5.9 millionOperating income of $2.5 million, up 143%Adjusted EBITDA of $3.7 millionFor 2025, SANUWAVE projects Q1 revenue of $8.4-9.0 million (45-55% YoY growth) and full-year revenue guidance of $48-50 million (47-53% growth). The company completed a 1-for-375 reverse stock split and raised $10.3 million through private placement in Q4 2024.

#SNWV SANUWAVE Announces Record Quarterly Revenues: Q4 FY2024 Financial Results

www.stocktitan.net/news/SNWV/sanuwave-annou...

#prfthundersnow #snwv

BREAKING NEWS: ( OTC: #SNWV ) SANUWAVE Health Announces 1-For-375 Reverse Stock Split

#StockMarket #News